HUTCHMED (China) Ltd.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: KYG4672N1198
HKD
21.48
0.42 (1.99%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About HUTCHMED (China) Ltd. stock-summary
stock-summary
HUTCHMED (China) Ltd.
Pharmaceuticals & Biotechnology
Hutchison China Meditech Limited is an investment holding company principally engaged in the manufacture and sale of drugs. Along with subsidiaries, the Company operates its business through two segments. The Manufacturing Business segment is engaged in the manufacture and distribution of drug products. The Distribution Business segment provides sales and marketing services to pharmaceutical manufacturers. The Company's products include prescription and over the counter (OTC) pharmaceuticals such as banlangen, fu fang dan shen tablets and shexiang baoxin pills and others, and consumer health products. In addition, the Company also develops targeted therapeutics and immunotherapies for oncology and autoimmune diseases.
Company Coordinates stock-summary
Company Details
22Nd Floor Hutchison House, 10 Harcourt Road None : 00000
stock-summary
Tel: 852 2121388844 852 21218200
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Simon To
Executive Chairman of the Board
Mr. Christian Hogg
Chief Executive Officer, Executive Director
Mr. Chig Fung Cheng
Chief Financial Officer, Executive Director
DR. Weiguo Su
Chief Scientific Officer, Executive Director
Ms. Edith Shih
Company Secretary, Non-Executive Director
Dr. Dan Eldar
Non-Executive Director
Mr. Paul Carter
Senior Independent Non-Executive Director
Dr. Karen Ferrante
Independent Non-Executive Director
Mr. Graeme Jack
Independent Non-Executive Director
Prof. Shu Kam Mok
Independent Non-Executive Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
589 Million
(Quarterly Results - Jun 2021)
Net Profit:
-462 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

HKD 20,587 Million ()

stock-summary
P/E

6.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.03

stock-summary
Return on Equity

37.76%

stock-summary
Price to Book

2.13